Skip to main content

CD19x22 CAR T Cells

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

  • RegistryNCT05098613
  • PhasePhase 1
  • StatusRecruiting
  • ConditionNon-Hodgkin Lymphoma
  • SponsorUniversity of Colorado, Denver
How CD19x22 CAR T Cells worksNCT050986131 min

What the film says

Read the transcript

CAR T cells aimed at a marker called CD19 can cure lymphomas nothing else touched. But they fail in more than half of patients, and one escape is simple: the lymphoma stops making CD19, and the cells lose sight of it.

The idea: give the cells two ways to see the cancer.

A patient's own T cells receive one gene that builds two receptors, for CD19 and for CD22, a second protein on the same cells. Lose one marker and the cell is still caught. The cells are infused once.

Colorado's trial, with Manali Kamdar, includes people whose lymphoma returned after earlier CAR T cells, and a group with lymphoma in the brain, where little works. First question: safety. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.

To determine the safety and tolerability of infusing CD19x22 CAR T, generated using a bicistronic vector, in adolescents and adults with R/R B-NHL, and to determine the recommended Phase II dose (RP2D). Secondary objectives for all subjects include: 1) Feasibility of manufacturing and infusion, 2) Safety of infusion and 3) Efficacy: Descriptive characterization of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) at Day +90.

As well, progression-free survival (PFS), overall survival (OS), duration of remission (DOR) and overall response rate (ORR) will be determined at 1 year. Efficacy will be descriptively stratified based on prior receipt of CAR-T cell therapy.

The study

How the trial runs.

This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). This trial will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3 trial design.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Age: ≥ 16 years of age with no upper age limit. (NOTE: the first three subjects on this trial must be ≥ 18 years of age.)
  • COHORT 1: Non-CNS B-NHL
  • Histologically confirmed aggressive B-cell NHL including the following types defined by World Health Organization (WHO) 2008:
  • Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr Virus (EBV)+ DLBCL of the elderly; OR
  • Primary mediastinal (thymic) large B cell lymphoma; OR
  • Transformation to DLBCL; OR

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.